^

Opinion

18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children

YOUR DOSE OF MEDICINE - Charles C. Chante MD -
The long-term immunogenicity and efficacy of hepatitis B (HBV) vaccination remain to the defined. We aimed to examine the long-term immunogenicity and efficacy of HBV vaccination with 3 different regimens over 18 years of follow-up. Methods: A total of 318 Chinese subjects receiving 3 different regimens of HBV vaccination (2-dose recombinant vs. 3-dose recombinant vs. 3-dose plasma-derived vaccines) without receiving a booster dose were recruited. The HBV serologic markers, including hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc), were determined at yearly follow-up. After 18 years, 88 subjects were still being followed up. Results: Compared with subjects receiving the 2-dose regimen, subjects receiving the 3-dose regimens had a significantly higher geometric mean titer of anti-HBs and a higher proportion had anti-HBs titers>10 m IU/mL during the 18 years of follow-up. There were no differences in these 2 parameters between subjects receiving the 3-dose plasma-derived vaccines. A total of 88 anamnestic responses were documented in 70 subjects (8 with initial anti-HBs titers <100m IU/Ml at 12 months and 7 with anti-HBs titers <10 m IU/mL before the anamnestic responses). No subject became positive for HBsAg. Three subjects had benign breakthrough HBV infection without leading to chronicity indicated by isolated anti-HBV infection without leading to chronicity indicated by isolated anti-HBc positivity. Conclusions: There was less long-term immunogenicity associated with the 2-dose regimen when compared with the 3-dose regimens of HBV vaccination. Because of the highly effective anamnestic responses, a booster dose was not necessary at least up to 18 years after the primary vaccination.

ANAMNESTIC

ANTI

DOSE

HBS

HBV

HSG

RECEIVING

REGIMENS

SUBJECTS

VACCINATION

YEARS

  • Latest
  • Trending
Latest
Recommended
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with